On April 25, Ge Longhui Pharmaceutical (603811.SH) released its report for the first quarter of 2024. During the reporting period, it achieved operating income of 153 million yuan, an increase of 3.54%; net profit attributable to shareholders of listed companies was 32.685 million yuan, a year-on-year decrease of 17.77%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 308.902 million yuan, a year-on-year decrease of 20.40%; and basic earnings per share were 0.1 yuan.
诚意药业(603811.SH)：一季度净利润3268.5万元，同比下降17.77%
Chengyi Pharmaceutical (603811.SH): Net profit of 32.685 million yuan in the first quarter, down 17.77% year on year
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.